Hawaii Biotech appoints Avantogen CEO to its board of directors
This article was originally published in Scrip
Hawaii Biotech, a biotechnology company focused on vaccine development, has appointed Dr William Ardrey to its board of directors. Dr Ardrey is CEO of Avantogen, which develops drugs in the oncology and vaccine markets, and which has a substantial stake in Hawaii Biotech. Dr Ardrey will both support Hawaii Biotech's development activities – the company recently began a trial into a vaccine for West Nile virus, and plans a Phase I trial for dengue fever next year – and bring investment to the company, with Avantogen planning to purchase additional shares in the company. The position is effective from October 21st.